During the 10-year period ending December 1976 ocular malignant melanoma developed in 99 patients in Alberta. To investigate the natural history of this disease we reviewed certain clinical and epidemiologic features of these cases. Of all the melanomas during that time 16% occurred in the eye, and of all the ocular malignant diseases 70% were malignant melanomas. The more malignant mixed cell tumours were much more frequent in the women than in the men, while the converse was true of the less malignant spindle cell melanomas. Within each cell type the women survived longer than the men. The actuarial 5-year survival rate of the entire group was 62%. Metastases occurred in 29 of the 99 patients; the liver was the only or initial site in 22 (76%). Our study shows that there has been no improvement in the survival rate of patients with ocular melanoma over the past 10 years. Our therapeutic methods must be improved.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan.
JCO Precis Oncol
January 2025
Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Purpose: Precision medicine plays an important role in the treatment of patients with advanced melanoma. Despite its high incidence in White patients, advanced melanoma is rare in Asian countries, hampering prospective clinical trials targeting the Asian population. This retrospective study aimed to elucidate the real-world molecular diagnoses and outcomes of Japanese patients with melanoma using comprehensive genome profiling (CGP).
View Article and Find Full Text PDFSelinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.
J Immunother Precis Oncol
February 2025
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Introduction: Uveal melanoma remains a disease with aggressive behavior and poor prognosis despite advances in clinical management. Because monotherapy with immune checkpoint inhibitors has led to limited improvement in response rates, combination with other agents that act on the biological basis of oncogenesis has been proposed as a possible therapeutic strategy.
Methods: We designed a phase 1b trial to test the safety and tolerability of selinexor in combination with immune checkpoint inhibitors in patients with advanced uveal melanoma.
UBE2G2 inhibits vasculogenic mimicry and metastasis of uveal melanoma by promoting ubiquitination of LGALS3BP.
Acta Pharm Sin B
December 2024
Department of Ophthalmology, the First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Uveal melanoma (UM) poses a significant lethality, with approximately 50% of those developing metastases surviving less than one year. In the progression of UM, vasculogenic mimicry (VM) induced by hypoxia plays a pivotal role, which also partially explains the resistance of UM to anti-angiogenic therapies. Nevertheless, the crucial molecular mechanisms underlying VM in the progression of UM remain unclear.
View Article and Find Full Text PDFLoss of NF1 accelerates uveal and intra-dermal melanoma tumorigenesis and oncogenic GNAQ transforms Schwann cells.
Cancer Res Commun
January 2025
University of British Columbia, Vancouver, BC, Canada.
NF1 encodes the multifunctional tumour suppressor protein, neurofibromin, which is best known for its causative role in Neurofibromatosis type 1 and in regulating MAPK signaling. Neurofibromin, in a context-specific manner, is involved in various tumorigenic processes, including those in melanocytes. This study investigated whether NF1 loss can collaborate with oncogenic GNAQ to promote melanoma in the dermis or eyes, where the G alpha q pathway is almost always activated.
View Article and Find Full Text PDFDifferentiating Choroidal Melanomas and Nevi Using a Self-Supervised Deep Learning Model Applied to Clinical Fundoscopy Images.
Ophthalmol Sci
November 2024
Liverpool Ocular Oncology Research Group, Department of Eye and Vision Science, Institute of Life Course and Medical Sciences (ILCaMS), University of Liverpool, Liverpool, United Kingdom.
Purpose: Testing the validity of a self-supervised deep learning (DL) model, RETFound, for use on posterior uveal (choroidal) melanoma (UM) and nevus differentiation.
Design: Case-control study.
Subjects: Ultrawidefield fundoscopy images, both color and autofluorescence, were used for this study, obtained from 4255 patients seen at the Liverpool Ocular Oncology Center between 1995 and 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!